Stockreport

Ikena Oncology Reports Fourth Quarter and Full Year 2023 Financial Results

Ikena Oncology, Inc.  (IKNA) 
PDF IK-930 continues to advance in the clinic now with an optimized formulation with improved pharmacokinetics IK-930 clinical update planned for 2H 2024 including addition [Read more]